This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Chimeric Antigen Receptor Phenotype Characterization
Chimeric Antigen Receptor (CAR) T-cell therapy has achieved remarkable success in treating hematological malignancies. Before practical application, in vitro characterization of CAR T-cells is necessary. This typically involves co-incubating CAR T-cells with tumor cells and peripheral blood mononuclear cells (PBMCs), followed by biochemical assays, microbiological assessments, and cytological analyses. Through this process, scientists can measure the effectiveness of CAR T-cells in killing individual tumor cells and evaluate safety-related outcomes such as cytotoxicity and cytokine production. With our flow cytometry, protein detection, metabolite analysis, and other high-throughput technologies, BioVenic offers comprehensive characterization services for preclinical studies of veterinary CAR therapy, facilitating research related to its development.
Fig.1. Schematic Overview of the Biomanufacturing of Chimeric Antigen Receptor (CAR)-T Cell Therapies.1,2
Transgene Delivery System Characterization
In veterinary CAR T-cell therapy, lentiviral transduction is commonly used for transfecting T cells. Due to the unique characteristics of immune cells, the viral purity required for lentiviral transduction of T cells is higher than that for regular stable cell lines. Our Transgene Delivery System Characterization service can assess the purity of lentivirus in the delivery system during the veterinary CAR transfection step and evaluate the copy number of the lentiviral vector, thereby helping to enhance the transfection efficiency of cells.
Chimeric Antigen Receptor Detection and Characterization
Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of veterinary CAR-T cell therapy from preclinical models to clinical adoption. Through our integrated protein assay platform, the veterinary CAR protein can be detected by flow cytometry, luminescence, immunoprecipitation, and microscopy. By assessing CAR expression in CAR-X cells during the discovery phase and preclinical studies on veterinary CAR therapies, scientists can verify whether the cells are functional.
| Flow Cytometry |
|
| Biochemical Assays |
|
| Microscopy |
|
Applications of Veterinary Chimeric Antigen Receptor Characterization
In veterinary medicine, CAR technology is being adapted to treat cancers in companion animals, such as dogs and cats, which often suffer from similar malignancies as humans. In various stages of veterinary CAR therapy development, detecting the expression levels of CAR genes and proteins holds significant importance. Our CAR characterization platform integrates a variety of services such as PCR, protein detection, and cell assays, providing valuable references for the development and application of various veterinary treatments.
- Ensuring the Normal Transfection of CAR Genes
By characterizing CAR genes, researchers can determine whether the construction of the vector is successful and whether the CAR gene sequence is capable of being expressed in the corresponding species or cell types. This process also helps in ensuring the efficiency of CAR transduction.
- Screening for Successfully Constructed CAR-X Cells
In CAR cell therapy, the active components that exert tumor-killing effects are the CAR-positive cells. Therefore, after CAR cell transduction, the most critical step is to detect antibodies of CAR-expressing cells. Researchers developing veterinary CAR therapies can screen for cells expressing CAR using characterization techniques such as flow cytometry.
- Quality Control of Cells in CAR Therapy Development
The packaging specifications and dosage of CAR cell products are expressed in terms of the number of CAR-T positive cells. Therefore, the transfection positivity rate of CAR is a mandatory quality control item in CAR-related cell therapies.
Why Choose Us?
Multiple CAR Characterization Techniques
With our PCR technology, protein characterization, and flow cytometry services, we can assist researchers in characterizing CARs from various aspects, including vector construction, CAR-positive cell screening, and downstream application evaluation.
Various Product and Service Resources
We have integrated multiple resources to provide a variety of reagents and services for detecting CAR expression, along with professional technical support to resolve challenges you may encounter in characterizing CARs during the development of veterinary CAR therapy.
Customized Services
Understanding the differences between animals and humans in CAR therapy development, we offer customized services tailored to the gene and protein expression characteristics of the studied animal species.
Characterizing CAR at the genetic and protein levels is fundamental to successfully constructing veterinary CAR cell therapies. BioVenic's experimental team possesses extensive experience in animal-related metabolite and protein detection, genetic analysis, and flow cytometry, enabling researchers to characterize CAR comprehensively. With our team of experts, we assist researchers in developing CAR cell therapies tailored to specific animal species. If you require animal-related CAR characterization research services, please contact us, and we will provide specialized services to meet your research needs.
References
- Image retrieved from Figure 1 "Schematic overview of the biomanufacturing of chimeric antigen receptor (CAR)-T cell therapies." Lombard-Banek et al., 2020, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). Without modification.
- Lombard-Banek, Camille, and John E. Schiel. "Mass spectrometry advances and perspectives for the characterization of emerging adoptive cell therapies." Molecules 25.6 (2020): 1396.